MedTrace Logo

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

NCT04334967 · Status: SUSPENDED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2020-09-16

No results posted yet for this study

Summary

This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19

Conditions

Interventions

DRUG

Hydroxychloroquine

Treatment arm medication will be administered on an outpatient basis. Due to the emergent health crisis, study drug will be delivered to patients by institution staff or contract courier using a non-contact protocol.

DIETARY_SUPPLEMENT

Vitamin C

Control arm supplement will be administered on an outpatient basis. Due to the emergent health crisis, study supplies will be delivered to patients by institution staff or contract courier using a non-contact protocol.

Sponsors & Collaborators

  • Center for Outcomes Research and Education

    collaborator UNKNOWN

  • Providence Cancer Center, Earle A. Chiles Research Institute

    collaborator OTHER

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Brian Kendal, MD · Providence Medical Group Infectious Disease

  • Trista Johnson, PhD, MPH · Providence Ambulatory Quality and Clinical Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-30
Primary Completion
2021-05-27
Completion
2022-05-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04334967 on ClinicalTrials.gov